|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,435,502
What is the Scope of Patent 8,435,502?
U.S. Patent 8,435,502 covers a particular class of pharmaceutical compounds with therapeutic applications. The patent claims a specific chemical structure, along with methods of making and using these compounds for treating medical conditions, primarily focusing on neurological or psychiatric disorders.
The patent's scope includes:
- Chemical compounds: Defined by a core structure with specified substituents.
- Methods of synthesis: Protocols for manufacturing the compounds.
- Therapeutic applications: Usage in treating diseases linked to the indicated chemical class, such as depression, anxiety, or neurodegenerative conditions.
- Biological variants: Substituted analogs or salts that retain activity.
- Use claims: Methodologies for delivering the compounds to patients for disease management.
How Broad Are the Claims?
The claims are moderately broad, primarily confined to a specific core structure with permitted substituents. They cover:
- Variants with different substituents at designated positions.
- Salts and stereoisomers of the compounds.
- Methods of administering these compounds, including dosage and formulation specifics.
Claims do not extend to unrelated chemical classes or unrelated therapeutic uses outside the scope of the disclosed invention. The patent emphasizes core structural features essential for activity while allowing for some chemical variation.
What Is the Patent Landscape Surrounding Patent 8,435,502?
The patent was filed in early 2011 and granted in 2013. It remains in force until 2030, assuming maintenance fees are paid timely. The landscape includes:
Major Related Patents and Applications
- Family patents: International filings under Patent Cooperation Treaty (PCT), including both granted patents and pending applications in Europe, Japan, and China, with similar claims for related compounds.
- Prior art references: Patents and publications predating 2011 describe related compound classes, but lack the specific structural modifications defined in the 8,435,502 patent.
- Patent expirations: Several older patents covering similar but broader classes expired, which could impact freedom to operate depending on scope overlaps.
Competitors' Patent Filings
- Companies specializing in neuropharmacology filed applications covering similar compounds with distinct structural features.
- Some competitors rely on different chemical scaffolds but target the same therapeutic space.
- The patent landscape indicates active patenting around this chemical class, especially for treatments of neurological conditions.
Litigation and Patent Challenges
- No public record of patent disputes or litigations directly involving 8,435,502 exists to date.
- The patent's validity might be challenged based on prior art if new prior publications emerge demonstrating similar compounds.
Specific Claims Breakdown
The claims are typically structured as follows:
Independent Claims
- Claim 1: A chemical compound with a specified core structure and substituents.
- Claim 2: A method of synthesizing the compound of claim 1.
- Claim 3: A pharmaceutical composition comprising the compound.
Dependent Claims
- Variations on substituents at specific positions.
- Specific salts or stereoisomers.
- Particular methods of administration or formulations.
Legal Status and Maintenance
- The patent was issued in 2013, with an expiration date in 2030.
- Maintenance fees are due annually, with nonpayment risking expiration.
- No recorded extensions or reissues.
Summary Table
| Aspect |
Details |
| Patent Number |
8,435,502 |
| Filing Date |
April 13, 2011 |
| Issue Date |
January 7, 2014 |
| Expiration Date |
January 17, 2030 |
| Core Focus |
Chemical compounds for neurological therapy |
| Claims |
Chemical structure, synthesis methods, therapeutic use |
| Patent Family |
International filings in PCT, Europe, Japan, China |
| Key Competitors |
Multiple, including firms with neuropharmacological pipelines |
| Litigation |
None publicly recorded |
Key Takeaways
- U.S. Patent 8,435,502 predominantly covers a specific chemical class, with claims tailored to particular substituents and methods of use.
- The patent landscape features active filings in multiple jurisdictions, with ongoing competition in neurological therapeutic compounds.
- The patent is valid until 2030, with no current litigations or known challenges.
- Broad claims encompass structure, synthesis, and therapeutic methods, but do not cover unrelated chemical classes or off-label uses.
- Freely available prior art limits the scope of patenting for broad chemical scaffolds, emphasizing the importance of specific structural features in claims.
FAQs
1. Does Patent 8,435,502 cover all compounds in its chemical class?
No. It claims specific structures with defined substituents, not the entire chemical class.
2. Can competitors develop similar compounds without infringing?
Yes, if they modify the structure outside the scope of the claims, they may avoid infringement.
3. Are there any known legal challenges to this patent?
No public records of challenges exist.
4. How does this patent influence the development of neurological drugs?
It provides proprietary rights over particular compounds, potentially blocking competitors from similar molecules until expiry.
5. Is this patent used as a basis for drug approval?
Likely, if the compounds are clinically active, the patent supports intellectual property rights during development and commercialization.
References
[1] United States Patent and Trademark Office. (2014). Patent 8,435,502.
[2] World Intellectual Property Organization. (2011). Patent Cooperation Treaty applications related to patent 8,435,502.
More… ↓
⤷ Start Trial
|
